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The initial results, complications and early follow-up of 74
patients undergoing percutaneous balloon mitral valvulo-
plasty in seven hospitals participating in a multicenter
registry are reported. Seventy-four patients with a mean
age of 53 years had 75 valvuloplasty procedures performed
over a 2.5 year period. Eighty-nine percent of the at-
tempted procedures were completed and resulted in an
increase in mean mitral valve area from 1.0 ± 0.04 to 2.0 ±
0.1 cm2 (p < 0.0001); the valve area increased ~50% ofthe
baseline valve area in 73% of the patients.
Major complications included procedure-related death
(2.7%), cardiac tamponade (6.7%), systemic embolism
(2.7%) and emergency surgery (6.7%). At a mean follow-
Percutaneous balloon mitral valvuloplasty has emerged as a
successful alternative to surgical commissurotomy in many
patients with mitral stenosis (1-3). Since the first descrip-
tions of this procedure by Inoue et al. (4) and Lock et al. (5),
several improvements in its application have been made.
First, the finding that a single balloon up to 25 mm in
diameter is not large enough to fully dilate most adult valves
(6,7) has led to the use of the double balloon technique (8)
and, more recently, to the use of larger single balloons (9).
Second, patient selection for a valve with the most mobility
and the least thickening, calcification and subvalvular dis-
ease has improved both the immediate hemodynamic results
of valvuloplasty (6,10,11) and the outcome during short-term
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up period of 14.6 months, the condition of the majority of
patients had improved, and 89% of 55 patients treated only
with valvuloplasty were in New York Heart Association
functional class I or II.
Thus, hemodynamic and clinical improvement can be
obtained in the majority of patients with mitral stenosis
treated with balloon valvuloplasty in multiple centers.
However, suboptimal results and major complications oc-
curred in a significant number of patients and may limit
this procedure to use by experienced operators in hospitals
with facilities for cardiac surgery.
(J Am Coli Cardiol1990;15:1221-6)
follow-up (12). Finally, good results have also been obtained
in patients after prior commissurotomy (13) and in those with
a stenotic bioprosthetic valve (14).
Most reports (1-3) to date from single centers with a large
volume and extensive experience have demonstrated good
initial results and low complication rates. In this report, we
review the experience with mitral valvuloplasty collected in
the multicenter M-Heart Valvuloplasty Registry, with par-
ticular emphasis on early patient outcome and the technical
problems and complications encountered by multiple oper-
ators.
Methods
Study patients. The study group consisted of 74 patients
undergoing 75 attempted valvuloplasty procedures from
May 1986 to January 1989 in seven hospitals (listed in the
Appendix). The M-Heart Valvuloplasty Registry was formed
in November 1987; data were collected retrospectively for
procedures before this date (24%) and prospectively there-
after. Baseline clinical information and hemodynamic results
were recorded on a standardized form and forwarded to a
0735-1097/90/$3.50
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Table I. Initial Hemodynamic Results of Mitral Valvuloplasty in
67 Completed Procedures
cardiac output was 4.2 ± 0.1 liters/min, yielding a calculated
mean mitral valve area of 1.0 ± 0.04 cm2 before valvulo-
plasty. The mean pulmonary artery pressure was 36 ± 2 mm
Hg, mean left atrial pressure was 26 ± I mm Hg and
pulmonary vascular resistance was 221 ± 29 dyne.s-cm-5.
Hemodynamic effects of valvuloplasty (Table 1). Percuta-
neous balloon mitral valvuloplasty was attempted 75 times in
the 74 patients (I patient had repeat valvuloplasty for reste-
nosis). The procedure was completed 67 times in 66 patients,
for a completion rate of 89%. The mean valve gradient
decreased from 15 ± I to 7 ± I mm Hg (p < 0.0000 and
mean mitral valve area increased from 1.0 ± 0.04 cm2 (range
0.5 to 1.7) to 2.0 ± 0.1 cm2(range 0.8 to 4.9) (p < 0.0001).
Cardiac output increased, mean left atrial and pulmonary
artery pressures decreased and pulmonary vascular resis-
tance was unchanged.
The procedure was considered technically successful if
mitral valve area increased by 2:50%; this increase occurred
in 54 patients (55 [73%] of 75 attempts). The valvuloplasty
procedure was terminated before completion in eight pa-
tients: left ventricular perforation occurred in four patients
during balloon inflation or positioning; two procedures were
aborted after a systemic embolism; one patient developed
hypotension and arrhythmia before balloon inflation; and the
balloon was never inserted in one patient in whom satisfac-
tory wire position was not attained. In an additional 12
patients, the procedure was judged unsuccessful based on a
suboptimal hemodynamic result defined as <50% increase in
mitral valve area due to either a complication (3 patients),
technical difficulties (3 patients) or an unknown cause (6
patients). Although patients with a suboptimal result tended
to have a smaller mean effective balloon dilating size, this
difference was not statistically significant.
central data analysis center. The number of patients studied
in each center was as follows (center number corresponds to
the listing in the Appendix): center I, 23; center 2, 15; center
3,8; center 4,8; center 5,2; center 6,8; and center 7, 10.
Informed consent was obtained as required by each center's
institutional review board.
Valvuloplasty procedure. The valvuloplasty procedure
used in all centers was similar to the procedure initially
described by Lock et al. (5). However, in the majority of
procedures, the double balloon technique as modified to
utilize a single atrial septostomy was used (l,8). All patients
systemically received heparin during the procedure. The
frequency of use of the combination of largest balloon
diameters for each of the 67 completed procedures was as
follows: 20 mm + 20 mm in 25; 18 mm + 18 mm in 5; 15 mm
+ 23 mm in I; 18 mm + 20 mm in 7; 15 mm + 20 mm in 5;
15 mm + 18 mm in 2; and 15 mm + 15 mm in I. The largest
diameter single balloon used in the remaining procedures
was 30 mm in 9; 25 mm in 3; 23 mm in 2; 20 mm in 6; and 15
mm in I. For the purposes of comparison, the effective
balloon dilating area (EBDA, in cm2) in double balloon
procedures was calculated as the sum of the area of two half
circles and the trapezoidal region subtending them using the
formula EBDA = 1T'/2 (a2+ b2) + (a + b)2, where a and bare
the radii of the balloons. The amount of shunting through the
artificially created atrial septal defect was calculated using
standard formulas, and a mixed venous oxygen content was
calculated as 3/4 x superior vena cava oxygen content + 1/4
x inferior vena cava oxygen content.
Follow-up. Patients were contacted by telephone during
July 1989 by a single research nurse at the coordinating
center. Information on clinical events after hospital dis-
charge, rehospitalization, New York Heart Association
functional class and the patient's subjective assessment of
functional improvement was ascertained. The rate of re-
stenosis was assessed clinically and included patients who
developed recurrent symptoms or died during the follow-up
period; patients who died of noncardiac causes and those
with a large (2:3 angiographic grades) increase in mitral
regurgitation were excluded from this category.
Statistics. All results are expressed as mean values ±
SEM. Hemodynamic and functional data were compared
before and after valvuloplasty using analysis of variance
with repeated measures (Newman-Keuls), and differences
were considered significant if the p value was <0.05.
Transmitral gradient (mm Hg)
Cardiac output (Iilers/min)
Mitral valve area (cm2)
Left atrial pressure (mm Hg)
Pulmonary artery pressure (mm Hg)
Pulmonary vascular resistance
(dyne's'cm- 5)
Before
\5 ± I
4.2 ± 0.1
1.0 ± 0.04
26 ± I
36 ± 2
22\ ± 29
After
7±1
4.8 ± 0.2
2.0 ± 0.1
17 ± I
31 ± 2
237 ± 30
p Value
<0.0001
<0.001
<0.0001
<0.001
<0.001
NS
Table 2. Major Complications in 75 ProceduresResults
Baseline clinical characteristics. The study group con-
sisted of 65 women and 9 men, with a mean age of 53 ± 2
years (range 14 to 92). All patients had symptoms of heart
failure: 17 patients were in functional class II, 45 were in
class III and 12 were in class IV. The baseline mean
transmitral gradient was 15 ± I mm Hg, and the mean
Left ventricular perforation and subsequent death
Cardiac perforation (tamponade)
Cardiac arrest
Systemic embolism
Mitral regurgitation (increase 2:2 grades)
No.
2
5
1
2
6
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Complications (Table 2). Sixteen major complications
occurred in 15 patients: left ventricular perforation and
subsequent death (n = 2), cardiac tamponade (n = 5),
cardiac arrest (n = 1), systemic embolism to the central
nervous system (n = 1) or the right coronary artery (n == 1)
and increase in mitral regurgitation of 2::2 grades (n = 6).
Additional minor complications included electrocardio-
graphic conduction abnormalities persisting for > 24 h
(n == 4), bleeding or hematoma formation requiring blood
transfusion (n =5), venous thrombosis (n = 1), hypotension
during balloon inflation causing transient neurologic symp-
toms (n == 3), arrhythmia requiring cardioversion (n = 1),
benign cardiac perforation (n = 2) and possible embolic
events without sequelae (n = 3).
Two patients died as a result of valvuloplasty (mortality
rate 2,7%), In one patient, left ventricular apical rupture
occurred during inflation of two 3 em long 18 mm diameter
balloons over guide wires positioned in the descending aorta,
and the patient died after emergency surgery, The second
patient also suffered from a perforation at an unknown point
during the procedure, developed cardiac arrest after pericar-
diocentesis and died 3 days after emergency surgery. Car-
diac perforation due to complications of the transseptal
procedure or inadvertent perforation by a wire occurred in
nine patients. In two patients, perforation resulted in peri-
carditis, but there were no hemodynamic changes. How-
ever, cardiac tamponade occurred in seven patients, requir-
ing pericardiocentesis (three patients) or surgery (four
patients including the two deaths described earlier). The
total emergency surgery rate was 6.7% (five patients).
Left ventriculography was performed both before and
after valvuloplasty in 48 patients. The degree of mitral regur-
gitation was unchanged or improved in 33 patients (69%),
increased by 1grade in 9 patients (19%) and increased by 2::2
grades in 6 patients (13%). Although mean effective balloon
dilating area was higher in patients who developed regurgita-
tion (4.05 ± 0.13 versus 3.54 ± 0.14 cm2/m2 , p = 0.03), the
range of balloon sizes was wide and the occurrence of mitral
regurgitation could not be predicted on the basis of balloon
size alone (r = 0.17, P = NS) (Fig. 1). Finally, the size of the
left to right shunt through the iatrogenically created atrial
septal defect was calculated in 45 patients and revealed a
pulmonary to systemic flow ratio 2:: 1.3 in eight patients (18%);
the average shunt ratio was 1.4 ± 0.1 (range 1.3 to 1.9).
Follow-up (Fig. 2 and 3). The procedure was not com-
pleted in eight patients, resulting in death (two patients) or
mitral valve replacement (four patients) before hospital
discharge. Three additional patients underwent early mitral
valve replacement for suboptimal valvuloplasty results. The
outcome in the remaining 63 patients was evaluated at a
mean of 14.6 ± 0.9 months after valvuloplasty,
Ten patients (16%) had clinical evidence of restenosis:
one patient underwent repeat dilation; four had mitral valve
surgery for restenosis (one had surgery for severe regurgita-
3.0 3.5 3.75 4.0 4.25
EBDA/BSA (em 21m 2)
Figure 1. Effect of balloon valvuloplasty on the development of
mitral regurgitation in 48 patients who underwent left ventriculog-
raphy before and after the procedure. The angiographic grade of
regurgitation increased by 2:2 grades in 13% (shaded bars), and by I
grade in 19% (hatched bars) and was unchanged in 69% (open bars).
There was no significant correlation (r = 0.17, p = NS) between
effective balloon dilating area normalized for body surface area
(EBDA/BSA) and the change in grade of mitral regurgitation.
tion and was not classified as having restenosis); four symp-
tomatic patients are awaiting further treatment and one died
from cardiac causes during the follow-up period. With mul-
tiple linear regression analysis, the occurrence of restenosis
could not be predicted by patient age, functional class, initial
or final valve gradient and valve area, the change in valve
area or balloon size used during the procedure. Among the
15 patients with an increase in regurgitation, 4 patients
required mitral valve replacement, but in only 1 did the
cause appear to be mitral regurgitation, and a 92 year old
women who was not a surgical candidate died of progressive
heart failure 6 weeks after valvuloplasty. The remaining 10
patients had clinical improvement despite an increase in
regurgitation.
Most patients (including the patient undergoing repeat
dilation) had clinical improvement, with an overall follow-up
technical success rate for valvuloplasty of 69% (51 of 74
patients) (Fig. 2). At follow-up evaluation, 49 (89%) of the 55
patients treated only by valvuloplasty were in functional
class I or II, and no patient had class IV symptoms (Fig. 3);
mean functional class improved from 2.9 ± 0.1 to 1.4 ± 0.1
(p < 0.0001).
Discussion
Reports from several institutions (1-3,15-17) have docu-
mented the beneficial effects of percutaneous balloon mitral
valvuloplasty for the relief of symptoms in adult patients
with acquired mitral stenosis. In this report, we extend these
observations to the results of this procedure from a multi-
hospital registry, in which each operator has less individual
experience. The immediate hemodynamic results of valvu-
loplasty for hospitals in the registry were the same as those
reported from single centers; transmitral gradient decreased
by approximately 50%, and mitral valve area increased by
100% from 1 to 2 cm2•
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with patients with an initial mitral valve area ;:::: 1 cm2
(n = 34). If it can be demonstrated that long-term clinical
improvement correlates better with the final valve area than
with the percent increase in area, a definition for procedural
success that incorporates final mitral valve area may be more
useful.
Other studies (10,11) have demonstrated that the imme-
diate hemodynamic results of valvuloplasty depend in part
on morphologic characteristics of the valve, which can be
assessed echocardiographically. Echocardiographic score
was not recorded in all registry hospitals, and patient selec-
tion was performed at the discretion of the individual inves-
tigators. It is important to note that all patients undergoing
valvuloplasty at each center were entered in the registry,
many before the utility of echocardiographic selection of
suitable candidates was widely appreciated.
Finally, a variety of alternative methods for performance
of balloon valvuloplasty have now been described (18,19).
All patients in this registry underwent anterograde valvulo-
plasty utilizing single or double balloons. There was a weak
correlation between balloon size and a suboptimal hemody-
namic result as previously described (6), but most of these
suboptimal hemodynamic results occurred with a single
balloon :::;25 mm in diameter.
Complications. The rate of most major complications was
similar to that reported by single centers with extensive
experience (3,20,21) and that in a preliminary report of the
National Heart, Lung, and Blood Institute Registry (22). In
particular, the rates of procedure-related death (0% to 4%),
systemic embolism (2% to 4%) and moderate increases in
mitral regurgitation (30% to 40%) were almost identical,
although the rate of cardiac tamponade appeared to be
somewhat higher in our multicenter study (6% to 7% versus
1% to 2%). Cardiac perforation occurred in nine patients,
and resulted in tamponade in seven patients. Emergency
surgery was required in four of these patients, and two
subsequently died, underlining the need to perform this
procedure only in hospitals with facilities for cardiac sur-
gery. Whether formal surgical backup should be required is
an individual institutional decision that depends on the
availability of operating rooms and the preferences of the
cardiology and cardiac surgical staff.
Is there a learning curve for the procedure? Although we
believe that operator experience is important in the perfor-
mance of mitral valvuloplasty and that training in transseptal
catheterization can reduce the incidence of cardiac perfora-
tion, we were unable to demonstrate a lower incidence of
this and other complications in the centers with greater
experience. There are several possible reasons why such a
"learning curve" could not be demonstrated from registry
data. First, the baseline level of operator experience with
transseptal catheterization and valvuloplasty differed at each
hospital. In some hospitals, the primary operator had re-
ceived fellowship training in valvuloplasty; at other institu-
4
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Figure 2. Outcome of all 74 patients included in the M-Heart
Balloon Mitral Valvuloplasty Registry. Excluding eight procedures
that were not completed and 3 patients who had early mitral valve
replacement (MVR) for suboptimal hemodynamic results, 63 pa-
tients underwent follow-up (FlU) evaluation at a mean of 14.6 ± 0.9
months (MO.) after valvuloplasty. Sixty-nine percent of all patients
had clinical improvement as a result of valvuloplasty, and 16% had
no change in condition or experienced recurrent symptoms.
Figure 3. Percent of patients in each New York Heart Association
(NYHA) functional class before (open bars) and after (hatched bars)
valvuloplasty among the 55 patients treated only with this proce-
dure. Mean functional class improved from 2.9 ± 0.1 to 1.4 ± 0.1
(p < 0.000l).
Clinical success rate. A technically successful procedure
(defined as a completed procedure resulting in ;::::50% in-
crease in valve area) was obtained in 73% of attempted
procedures, with a suboptimal hemodynamic result occur-
ring in 16% of the procedures. This success rate was the
same as that obtained in the initial Massachusetts General
Hospital experience (6) when the same definition of success
is applied. This arbitrary definition of success was chosen so
as not to exclude patients with a severely stenosed valve (for
example, valve area <0.7 cm2) in whom the final result might
not have exceeded a given final valve area, but in whom we
observed clinical improvement. In this regard, there were no
significant differences in success rate or percent change in
any hemodynamic variable or functional class in patients
with an initial mitral valve area <1cm2 (n = 36) as compared
JACC Vol. 15, No.6
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tions, the primary operator's trammg consisted only of
observing one or two procedures at a demonstration course.
Second, several hospitals "imported" experienced opera-
tors to assist in the performance of some or all of their
procedures. Third, each center may learn from problems
that are encountered at a different rate. Finally, the number
of procedures necessary to lower the rate of complications
may be greater than the number performed at even our most
experienced center. Thus, if a learning curve in the perfor-
mance of mitral valvuloplasty exists, it may be best demon-
strated by comparing the early and late experience in a single
center, rather than comparing small differences in the mul-
tiple centers of a registry.
Postvalvuloplasty regurgitation. Moderate and severe in-
creases in mitral regurgitation of :::::2 angiographic grades
occurred in 13% of patients, a rate similar to that found in
other studies (23). Although the development of increased
regurgitation was weakly correlated with balloon size, it is
likely that other factors also contribute to its occurrence.
One recent report (3) suggests that a posterior mitral leaflet
tear may lead to severe mitral regurgitation in some patients
with a calcified valve and extensive subvalvular disease. The
majority of patients developing moderate grades of mitral
regurgitation can be managed medically; only I of 15 patients
in this study required mitral valve replacement for regurgi-
tation during the 14.6 month follow-up period.
Atrial septal defect. The size of atrial septal defect was
estimated by measuring the intracardiac left to right shunt
after valvuloplasty (24). Our results demonstrating a mea-
surable shunt in 18% of patients and a pulmonary to systemic
flow ratio> 1.3 in 7% of patients are similar to the previously
reported rates of 20% (12) and 8.5% (3), respectively.
Although a retrograde valvuloplasty technique that does not
require dilation of the interatrial septum can reduce the
incidence of shunts (18,19), the majority of these septal
defects appear to close during short-term follow-up (12).
Follow-up. Clinical follow-up was obtained in all patients
a mean of 14.6 months after valvuloplasty and revealed
excellent symptomatic improvement, as previously reported
by other investigators (3,12,16). Clinical evidence of resteno-
sis developed in 10 (16%) of the 63 patients undergoing
follow-up evaluation. Included in this group were nine
patients who developed recurrent symptoms and one patient
who died in part because of recurrent congestive heart
failure. With multivariate analysis, the occurrence of reste-
nosis could not be predicted by any pre- or postvalvuloplasty
hemodynamic variable, the change in valve area or balloon
size used during the procedure.
It is possible that the rate of restenosis based on hemo-
dynamic or echocardiographic valve assessment may differ
from the rate assessed by other means. However, Palacios
et a1. (12) obtained follow-up catheterization or echocardio-
graphic data in 71 patients a mean of 13 months after
valvuloplasty and demonstrated a loss of :::::50% of the initial
gain in mitral valve area in a similar proportion of patients
(18%). Furthermore, the restenosis rate was substantially
higher in patients with a high echocardiographic score for
leaflet thickening or immobility, valvular calcification or
subvalvular thickening (42% versus 4%) (12).
Clinical implications. In this report, we have demon-
strated that hemodynamic and clinical improvement can be
obtained in the majority of adult patients with acquired
mitral stenosis treated with mitral valvuloplasty in multiple
centers. However, suboptimal results and major complica-
tions occurred in a significant number of patients. For this
reason, we believe that mitral valvuloplasty should be per-
formed only in centers with facilities for cardiac surgery and
by operators experienced in transseptal catheterization tech-
niques.
Finally, we believe that despite the early success ofmitral
valvuloplasty, it should remain an investigational technique
at the current time. Surgical commissurotomy is a highly
successful technique with a long record of experience (25),
whereas the long-term outcome of balloon valvuloplasty is
not yet known and the rate of certain complications may be
higher. In addition, the criteria for optimal patient selection
for balloon mitral valvuloplasty are still evolving (12) and
technical aspects of the procedure are changing.
Appendix
Participating hospitals in the M-Heart Balloon Valvuloplasty Registry are as
follows:
Center 1) University of Pennsylvania, Philadelphia, Pennsylvania. Principal
Investigator: Howard C. Herrmann, MD. Coinvestigators: William G. Kuss-
maul. MD. Warren K. Laskey, MD. John W. Hirshfeld, Jr., MD. Carol A.
Davis. RN.
Center 2) Temple University, Philadelphia, Pennsylvania. Principal Inves-
tigator: J. Patrick Kleaveland, MD. Coinvestigators: Ezra Deutsch. MD,
Steve Heilbrunn, MD.
Center 3) University of Florida, Gainesville, Florida. Principal Investiga-
tors: James A. Hill. MD. Carl J. Pepine, MD. Coinvestigators: Charles R.
Lambert. MD, PhD, Eilleen Hanberg, RN.
Center 4) Medical College of Virginia, Richmond, Virginia. Principal
Investigators: Michael Cowley, MD. George Vetrovec, MD. Coinvestigator:
Kim Cook. RN.
Center 5) Thomas JelIerson University, Philadelphia, Pennsylvania. Princi-
pal Investigator: Sheldon Goldberg. MD. Coinvestigators: Andrew Zalewski.
MD. Michael Savage. MD, Patricia Wilson. RN.
Center 6) South Miami Hospital, Miami, Florida. Principal Investigator:
James R. Margolis, MD. Coinvestigators: Jose C. Martin, MD, Daniel
Krauthamer. MD. Juan C. Garcia MD, G. T. Welcom. RN.
Center 7) Florida Hospital Medical Center, Orlando, Florida. Principal
Investigators: Michael A. Nocero. Jr.. MD. Hall B. Whitworth. MD. Coin-
vestigators: Andrew Taussig, MD. Susie Lee. RN.
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